Bezjak A, et al. - Researchers assessed stereotactic body radiotherapy (SBRT) in patients with centrally located non–small-cell lung cancer (NSCLC), focusing on the maximum tolerated dose (MTD), efficacy, and toxicity of SBRT in these patients in a phase I/II study (NRG Oncology/RTOG 0813). They used a dose-escalating, five-fraction SBRT schedule that ranged from 10 to 12 Gy/fraction (fx) and was delivered over 1.5 to 2 weeks to medically inoperable patients with biopsy-proven, positron emission tomography–staged T1 to 2 (≤ 5 cm) N0M0 centrally located NSCLC. Overall 120 patients were recruited and followed-up for a median of 37.9 months. In this study, the MTD was 12.0 Gy/fx. They noted 7.2% dose-limiting toxicities and high rates of tumor control in relation to 12.0 Gy/fx as MTD. This medically inoperable group of mostly elderly patients with comorbidities demonstrated outcomes that were comparable to those of patients with peripheral early-stage tumors.